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I feel honored to be asked by theMovement Disorders
journal to contribute my thoughts to the controversy on
how to treat patients with Wilson’s disease, particularly
during the initial period. I am doubly honored to cross
swords on this topic with Professor John Walshe, who
has contributed so much to the treatment of Wilson’s
disease.1,2 As I have said in other settings, a whole gen-
eration of patients with Wilson’s disease owe their lives
to the pioneering work of Professor Walshe.
But then was then and now is now, and the two are not
the same. Drugs that do wonderful things in one era,
along with some damage, tend to be replaced by drugs in
another era, drugs that still do wonderful things but with
much less damage. That is exactly the situation we have
at present with penicillamine. Its era is over. It is far too
toxic to use when we have drugs that are just as effective
and much safer.
One of the major problems with penicillamine occurs
when it is used for the initial treatment of the patient
presenting with neurologic disease.3 There is a major risk
that the patient will be made permanently worse neuro-
logically. Take the following case as an example of the
disaster awaiting patient and physician when they use
penicillamine in this situation. The patient was an attrac-
tive 27-year-old woman working on her master’s degree.
She developed depression, a mild dysarthria, and mild
tremor, and was diagnosed as having Wilson’s disease.
She was started on 1.0 g penicillamine per day and over
4–8 weeks became much worse. Her dysarthria and
tremor progressed, and she developed mild dystonia of
the face, trunk, and limbs. Her dose of penicillamine was
doubled. Over a 3–4-month period she worsened disas-
trously. Her dysarthria became severe, her posture
changed because of the dystonia such that her back be-
came continuously curved, and dystonia and tremor of
her upper extremities worsened to the point where she
was essentially unable to carry out even simple care tasks
such as feeding herself. Her gait became distorted and
uncomfortable, limiting her walking to very short
stretches. Her face became grotesquely distorted with
chronic drooling. Dysphagia developed and became se-
vere enough to lead to frequent choking episodes, but the
patient refused gastrostomy. This all happened 20 years
ago, and despite many years of penicillamine therapy,
bringing her copper status under good control, the patient
has never recovered. She lives today crippled without
hope of a meaningful social or working life. She has
attempted suicide several times.
Was this patient’s life destroyed by penicillamine?
Some would argue that the real culprit was Wilson’s
disease and the toxicity of copper, not the drug designed
to get rid of that copper. However, I can almost guaran-
tee, as close as anyone can ever come to guaranteeing
anything in medicine, that if I had that patient to treat
now at the beginning of her presentation, she would have
been able to subsequently live a healthy, essentially nor-
mal life. This tragedy was unavoidable then. It is inex-
cusable now.
Is penicillamine-induced worsening rare and this pa-
tient’s course an isolated occurrence? Unfortunately not.
Along with Carol Terry, then President of the Wilson’s
Disease Association, we did a retrospective survey of the
Association members who had presented with neurologic
symptoms and who had been treated with penicillamine.3
Of 27 respondents, 13 had shown initial deterioration,
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usually within 2–6 weeks of starting treatment, and six
never recovered to their pre-penicillamine baseline. Most
of this latter group were severely disabled, much like the
patient we described here.
These data indicate that 50% of the time, patients of
this type worsen on penicillamine, and 50% of that
group, or almost 25% of the original group, are left with
more serious disability than they started with. Retrospec-
tive surveys can be criticized, and I do not defend the
numbers as being highly rigorous. However, the numbers
clearly indicate that there is a high risk with penicilla-
mine treatment to this type of patient, so much so that I
often draw the analogy that the patient presenting neu-
rologically has a ticking bomb within their head and
penicillamine is just the drug to light the fuse. A roughly
25% probability of a disastrous result and ruined life is
just too great a risk to take when today we have safer
alternatives.
Some might argue that these deteriorating patients are
simply going through the natural course of the disease,
and that these worsenings were fated to occur because
the damage had already set them in motion, no drug
could have prevented them, and penicillamine should not
be blamed for them. There are overwhelming arguments
that this is not the case. First, the penicillamine-induced
deteriorations are sudden, explosive worsenings within a
few weeks, and do not follow the more gradual time
course of each patient’s history prior to diagnosis and
treatment. An example is a 22-year-old man who pre-
sented elsewhere with tremor, drooling, and mild dysar-
thria. He was placed on penicillamine and over a 6-week
period showed significant deterioration. His dysarthria
became worse, his facial dystonia and drooling were
worse, and he had developed dystonia of all limbs. He
could barely be understood and was bedridden. At this
6-week point in his penicillamine therapy, we saw him
for the first time. Magnetic resonance imaging (MRI) of
the brain at this time showed typical basal ganglia lesions
but no white matter lesions. Because we thought the
patient had already gone through penicillamine-induced
worsening, we elected to leave him on penicillamine.
Within another 4 weeks the patient had deteriorated fur-
ther to the point of being anarthric and even less mobile
in bed. He had also developed a seizure disorder. A
repeat MRI showed new, severe white matter lesions.3
We have not seen such a rapid, explosive deterioration in
brain MRI in numerous other neurologic patients we
have followed who were not on penicillamine.
A second, overwhelming piece of evidence that the
kind of deterioration induced by penicillamine is not
part of the preordained natural history of the disease is
that if the patients are treated with a different drug, this
type of worsening does not occur.4–6 I will turn to pre-
ferred therapy for this type of patient subsequently in this
article.
The reason penicillamine is so prone to induce neuro-
logic worsening is not known with certainty. We have
studied rats loaded with copper by high copper diets and
found that during initial penicillamine treatment, there is
a tendency for brain copper levels to increase further.
Initial treatment with penicillamine causes a huge cupru-
resis, and the only way the copper can get to the kidneys
is through the bloodstream. Therefore, one can speculate
that during the movement of large amounts of copper,
much of it from the liver, through the bloodstream, brain
copper increases further, causing further toxicity. How-
ever, it can be hypothesized that penicillamine causes
shifts in copper from various intraneuronal locales to
others, causing toxicity in that manner, or there may be
other mechanisms. Regardless of mechanism, it is clear
that penicillamine therapy is a terrible risk in these
patients.
What are the alternatives to penicillamine for the neu-
rologically presenting patient? We have developed zinc
acetate (Galzin®, Gate Pharmaceutical Co, Montgom-
eryville, PA, U.S.A.) for the maintenance therapy of Wil-
son’s disease, and it was approved in January 1997 by
the FDA for this purpose.7–23 Zinc has been extensively
used by the Hoogenraad group in the Netherlands,24–26
and they use it for initial therapy in all patients with
Wilson’s disease. They have not reported any problems
with this approach, but they also have not reported any
detailed neurologic functional studies so that one can
determine whether there has been some deterioration and
if so, how much. I have personally started three neuro-
logically presenting patients on zinc, and while two did
well, one did have significant progression of tremor dur-
ing the first few months of therapy. Zinc does not have
the risk of causing explosive worsening by moving large
amounts of copper around the body, but it is a slow-
acting decoppering agent, and the patient’s disease can
show some progression during the 4–6 months it takes
zinc to reduce copper below the toxic threshold. For this
reason, I am not enthusiastic about the use of zinc for
initial therapy, but it is a better and safer choice than
penicillamine.
Trientine is officially approved in the United States to
use as an alternative to penicillamine when the patient is
intolerant of penicillamine. Because of this restriction, it
has not seen extensive use and there is little data on its
risks of causing neurologic deterioration. We are aware
of one unpublished patient who deteriorated on trientine,
but because studies have not been published, there is no
way of knowing the actual risk of deterioration on trien-
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tine. Because it is a chelator, it probably shares with
penicillamine some risk, but because it is not a reductive
chelator like penicillamine, its in vivo properties may be
different. A study is needed to define the risk of initial
treatment with trientine.
Over recent years we have developed tetrathiomolyb-
date (TM) for initial treatment of the neurologic pa-
tient.4–6 TM is extremely fast acting yet safe, and be-
cause it acts through an entirely different mechanism, it
does not share the risk with penicillamine of making
patients deteriorate neurologically.
To study TM, we set up a detailed protocol that in-
volved weekly quantitative evaluation of speech function
and neurologic function other than speech. TM was
given for an 8-week period. In all, 55 patients have been
studied4–6 (subsequent unpublished studies). Only two
patients in this group showed any deterioration. One of
these was a patient who deteriorated in the month or two
after discharge and who we only treated for 6 weeks, a
change we made with a few patients to reduce their time
away from home. Since that result, we have gone back to
an exclusive 8-week protocol. We do not know why the
other patient deteriorated. In both cases, while the quan-
titative neurologic score exceeded our limits and was
therefore deemed significant, the actual clinical deterio-
ration was rather mild.
Most important, 53 of 55 patients (96%) of carefully
evaluated patients showed no evidence of deterioration.
These patients were then placed on zinc maintenance
therapy, and over the next 2 years, brain damage was
slowly repaired. Within 1–2 years of initiating therapy,
the recovery of these patients was generally remark-
able.4–6 Mild patients generally showed complete recov-
ery, moderately affected patients generally only had
slight residual, and even some of the severely affected
patients recovered enough to live a fairly normal life.
TM has shown no toxicity per se, but because it is so
potent, with overtreatment it can render the bone marrow
temporarily copper-deficient, leading to easily reversible
bone marrow suppression. Stopping the drug temporarily
quickly reverses this problem. We have seen this effect
primarily with higher doses that we have used in the past.
With our current dose (120 mg daily), such a response is
rare.
The main disadvantage of TM is its availability. The
drug needs to be especially prepared for human use, and
it must be carefully stored, with air excluded, to maintain
stability. Thus, TM is generally not accessible for occa-
sional use. Our use is experimental and is an investiga-
tional new drug study filed with the FDA. Until now, we
have not sought permission to share the drug with phy-
sicians elsewhere because the protocol was fairly com-
plicated. With increasing experience and simplification
of the protocol, we may be able to share the drug. For
those patients who are capable of coming to our Medical
Center, the clinical trial provides free care and hospital-
ization. We also have a recently funded grant, along with
Dr. Michael Schilsky of Albert Einstein College of
Medicine, to compare trientine and TM in the initial
treatment of neurologically presenting Wilson’s disease.
The initial treatment of patients presenting with liver
disease requires a triage to determine whether the patient
is unlikely to survive without liver transplantation. We
use the prognostic index of Nazer and colleagues27 a
one part of that determination. If medical therapy is
elected, we use a combination of trientine and zinc. Tri-
entine is used to get a relatively quick and sizable nega-
tive copper balance, and zinc is used, at least initially, for
its induction of hepatic metallothionein, which will bind
intrahepatic copper and theoretically reduce further cop-
per damage. However, the best therapy or combination
of therapies has not been established rigorously for this
type of patient. For example, TM, which is life-saving in
copper-poisoned sheep who otherwise die of hepatic fail-
ure, should be examined.
For maintenance therapy, which includes presymp-
tomatic patients from the beginning and pediatric pa-
tients, the clear treatment of choice is zinc. Penicillamine
has such a long list of acute, subchronic, and chronic
toxicities that it should never be used in the treatment of
Wilson’s disease.23 Beyond the known toxicities are
theoretical side effects not yet reported but which could
be disastrous. For example, studies in rats and chickens
have shown that penicillamine causes damage to colla-
gen and elastin, including that of blood vessels.28,29One
worries about strokes, aneurysms, and the like in patients
treated for a lifetime with penicillamine. Trientine ap-
pears to be less toxic than penicillamine for maintenance
therapy but still has a list of significant toxicities.
In contrast, zinc used in maintenance therapy is free of
side effects except for an occasional patient who has
mild gastric intolerance of zinc, and this can usually be
mitigated or eliminated by some simple maneuvers.22
We are aware that Dr. Walshe has treated patients who
had problems with gastric intolerance, but he has used
zinc sulfate rather than the zinc acetate we use, and the
sulfate salt is more irritating to the stomach.
There have also been occasional reports of zinc fail-
ures, including one from Dr. Walshe.30,31 However, re-
view of these cases always reveals that there are no data
to indicate that the patient was actually taking their zinc
prior to becoming ill. Because periodic noncompliance
reaches as high as 30%, even in our carefully followed
and monitored patients,22 each of these cases is probably
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the result of noncompliance. Any Wilson’s disease pa-
tient not taking anti-copper medication will deteriorate.
Compliance with zinc therapy is easily checked by fol-
lowing 24-hour urine zinc and copper.
Finally, zinc is the treatment of choice during preg-
nancy in women with Wilson’s disease. Zinc is not ter-
atogenic, and we have followed 18 pregnancies on zinc
therapy with generally good results.22 Penicillamine is
teratogenic in animals and people,32–34 and trientine is
known to be teratogenic in animals.34
Returning to the main topic of this controversy, wheth-
er penicillamine should be used for initial therapy of the
neurologically presenting patient with Wilson’s disease,
it turns out, unfortunately for Dr. Walshe’s side of the
argument, that there is no controversy at all. Penicilla-
mine should not be used, pure and simple. It is far too
dangerous, far too likely to produce a severely and per-
manently disabled patient. In contrast, TM looks good at
preserving neurologic function and allowing most pa-
tients the opportunity to recover and return to a produc-
tive life. If TM is unavailable to a given patient, zinc or
trientine are far safer and better choices for treating this
type of patient.
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